Healix

Mandated Payor Switching with Infliximab (IFX) Bioimilars

Authors:
Harry E. Sarles, MD, FACG – DHAT Research Institute, Richardson, TX
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Sugar Land, TX
Thomas C. Hardin, PharmD – Healix Infusion Therapy, Sugar Land, TX

View Poster

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.

FacebookTwitterLinkedInarrow1arcsearchiconowdtnotfound